BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 26852845)

  • 1. Influence of 24-Nor-Ursodeoxycholic Acid on Hepatic Disposition of [(18)F]Ciprofloxacin, a Positron Emission Tomography Study in Mice.
    Wanek T; Halilbasic E; Visentin M; Mairinger S; Römermann K; Stieger B; Kuntner C; Müller M; Langer O; Trauner M
    J Pharm Sci; 2016 Jan; 105(1):106-12. PubMed ID: 26852845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of ursodeoxycholic and norursodeoxycholic acid as substrates of the hepatic uptake transporters OATP1B1, OATP1B3, OATP2B1 and NTCP.
    König J; Klatt S; Dilger K; Fromm MF
    Basic Clin Pharmacol Toxicol; 2012 Aug; 111(2):81-6. PubMed ID: 22333292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver.
    Denk GU; Maitz S; Wimmer R; Rust C; Invernizzi P; Ferdinandusse S; Kulik W; Fuchsbichler A; Fickert P; Trauner M; Hofmann AF; Beuers U
    Hepatology; 2010 Nov; 52(5):1758-68. PubMed ID: 21038414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice.
    Kok T; Bloks VW; Wolters H; Havinga R; Jansen PL; Staels B; Kuipers F
    Biochem J; 2003 Feb; 369(Pt 3):539-47. PubMed ID: 12381268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defective canalicular transport and toxicity of dietary ursodeoxycholic acid in the abcb11-/- mouse: transport and gene expression studies.
    Wang R; Liu L; Sheps JA; Forrest D; Hofmann AF; Hagey LR; Ling V
    Am J Physiol Gastrointest Liver Physiol; 2013 Aug; 305(4):G286-94. PubMed ID: 23764895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice.
    Halilbasic E; Fiorotto R; Fickert P; Marschall HU; Moustafa T; Spirli C; Fuchsbichler A; Gumhold J; Silbert D; Zatloukal K; Langner C; Maitra U; Denk H; Hofmann AF; Strazzabosco M; Trauner M
    Hepatology; 2009 Jun; 49(6):1972-81. PubMed ID: 19475687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of ABC transporters on the excretion of ciprofloxacin assessed with PET imaging in mice.
    Hernández-Lozano I; Wanek T; Sauberer M; Filip T; Mairinger S; Stanek J; Traxl A; Karch R; Schuetz JD; Langer O
    Eur J Pharm Sci; 2021 Aug; 163():105854. PubMed ID: 33865975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of norUDCA and UDCA in obstructive cholestasis in mice.
    Fickert P; Pollheimer MJ; Silbert D; Moustafa T; Halilbasic E; Krones E; Durchschein F; Thüringer A; Zollner G; Denk H; Trauner M
    J Hepatol; 2013 Jun; 58(6):1201-8. PubMed ID: 23369794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
    Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
    Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4.
    Köck K; Ferslew BC; Netterberg I; Yang K; Urban TJ; Swaan PW; Stewart PW; Brouwer KL
    Drug Metab Dispos; 2014 Apr; 42(4):665-74. PubMed ID: 24154606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 24-Norursodeoxycholic acid reshapes immunometabolism in CD8
    Zhu C; Boucheron N; Müller AC; Májek P; Claudel T; Halilbasic E; Baazim H; Lercher A; Viczenczova C; Hainberger D; Preglej T; Sandner L; Alteneder M; Gülich AF; Khan M; Hamminger P; Remetic J; Ohradanova-Repic A; Schatzlmaier P; Donner C; Fuchs CD; Stojakovic T; Scharnagl H; Sakaguchi S; Weichhart T; Bergthaler A; Stockinger H; Ellmeier W; Trauner M
    J Hepatol; 2021 Nov; 75(5):1164-1176. PubMed ID: 34242699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic transport mechanisms of cholyl-L-lysyl-fluorescein.
    de Waart DR; Häusler S; Vlaming ML; Kunne C; Hänggi E; Gruss HJ; Oude Elferink RP; Stieger B
    J Pharmacol Exp Ther; 2010 Jul; 334(1):78-86. PubMed ID: 20388726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of transporters in the disposition of the selective phosphodiesterase-4 inhibitor (+)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid in rat and human.
    Kalgutkar AS; Feng B; Nguyen HT; Frederick KS; Campbell SD; Hatch HL; Bi YA; Kazolias DC; Davidson RE; Mireles RJ; Duignan DB; Choo EF; Zhao SX
    Drug Metab Dispos; 2007 Nov; 35(11):2111-8. PubMed ID: 17686907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nor-Ursodeoxycholic Acid as a Novel Therapeutic Approach for Cholestatic and Metabolic Liver Diseases.
    Halilbasic E; Steinacher D; Trauner M
    Dig Dis; 2017; 35(3):288-292. PubMed ID: 28249255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Organic Anion Transporting Polypeptide (OATP) 1B3 is a Significant Transporter for Hepatic Uptake of Conjugated Bile Acids in Humans.
    Pan Q; Zhu G; Xu Z; Zhu J; Ouyang J; Tong Y; Zhao N; Zhang X; Cheng Y; Zhang L; Tan Y; Li J; Zhang C; Chen W; Cai SY; Boyer JL; Chai J
    Cell Mol Gastroenterol Hepatol; 2023; 16(2):223-242. PubMed ID: 37146714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis.
    Sombetzki M; Fuchs CD; Fickert P; Österreicher CH; Mueller M; Claudel T; Loebermann M; Engelmann R; Langner C; Sahin E; Schwinge D; Guenther ND; Schramm C; Mueller-Hilke B; Reisinger EC; Trauner M
    J Hepatol; 2015 Apr; 62(4):871-8. PubMed ID: 25463533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of multiple efflux transporters in hepatic disposition of fexofenadine.
    Matsushima S; Maeda K; Hayashi H; Debori Y; Schinkel AH; Schuetz JD; Kusuhara H; Sugiyama Y
    Mol Pharmacol; 2008 May; 73(5):1474-83. PubMed ID: 18245269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatobiliary transport of bile acids and organic anions.
    Takikawa H
    J Hepatobiliary Pancreat Surg; 2002; 9(4):443-7. PubMed ID: 12483266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Amino Acid/Drug Transporters for Renal Transport of [
    Ono M; Baden A; Okudaira H; Kobayashi M; Kawai K; Oka S; Yoshimura H
    Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27754421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of [
    Yagi Y; Kimura H; Okuda H; Ono M; Nakamoto Y; Togashi K; Saji H
    Nucl Med Biol; 2019; 74-75():25-31. PubMed ID: 31450072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.